Until 1996, AIDS was the leading cause of deaths from HIV infection. In 2010, because of introduction of powerful antiretroviral therapies, AIDS represented less than 25% of deaths. Cancer has become the leading cause of death in this population, and, because of smoking and immunosuppression, lung cancer risk is more important than in general population. Furthermore, treatment is more difficult, due to potential interactions between antiretroviral and anticancer therapies, to comorbidities and to tumor aggressiveness. Research will focus on molecular biology, immunotherapies and lung cancer screening in order to improve survival of HIV patients with lung cancer. For all these reasons, HIV patients must be included in clinical trials.
Keywords: Antiretroviral and chemotherapies interactions; Cancer du poumon; Epidemiology; HIV infection; Infection par le VIH; Interactions entre les antirétroviraux et les chimiothérapies; Lung cancer; Épidémiologie.
Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.